Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07107490

A PHASE I STUDY OF ALPS12 IN PATIENTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER

This study is a phase I, open-label, multicenter trial designed to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of ALPS12 in patients with extensive-stage small cell lung cancer. The study consists of two parts: a dose-escalation part and an expansion part.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Extensive Stage Small Cell Lung Cancer

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Queen Mary Hospital, Hong Kong

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Aged >18 years at time of informed consent
  • Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1
  • Histologically documented extensive stage small cell lung cancer
  • Disease recurrence documented after at least one prior systemic therapy.
  • Confirmed availability of representative archival tumor specimens or fresh tumor specimen.
  • Measurable disease per RECIST v.1.1.
  • Adequate hematologic and end organ function

Exclusion criteria

  • Pregnant or breastfeeding, or intending to become pregnant or breastfeeding during the study
  • History or complication of clinically significant autoimmune disease
  • a positive HIV antibody test at screening
  • Active hepatitis B or hepatitis C
  • Prior treatment with anti-CD137 antibody drugs, anti-CD3 antibody drugs, and/or DLL3-targeted therapies
  • Patients who have received any investigational or approved anticancer therapy, including hormone therapy and/or radiotherapy, within 21 days prior to the first administration of the investigational drug.
  • History of Grade 4 immune-related adverse events caused by prior anti-PD-L1/PD-1 antibody drugs or anti-CTLA-4 antibody drugs (excluding asymptomatic elevations in serum amylase/lipase)
  • Patients who discontinued immunotherapy due to Grade 3 immune-related adverse events caused by prior anti-PD-L1/PD-1 antibody drugs or anti-CTLA-4 antibody drugs (excluding asymptomatic elevations in serum amylase/lipase), and/or patients who experienced Grade 3 immune-related adverse events caused by immunotherapy within 6 months prior to the first administration of the investigational drug
  • Patients who received a live attenuated vaccine within 4 weeks prior to the first administration of the investigational drug
  • History or clinical evidence of primary central nervous system (CNS) malignancy, symptomatic CNS metastases, CNS metastases requiring any anti tumor treatment, or leptomeningeal disease
  • Current or past CNS diseases (e.g., stroke, epilepsy, CNS vasculitis, neurodegenerative diseases)

Treatment and study plan

ALPS12

Drug

ALPS12 as an IV infusion

Obinutuzumab

Drug

Obinutuzumab as an IV infusion

Primary outcomes

  1. All part : Adverse events of ALPS12[safety and tolerability]

    Time frame: From screening until study completion or treatment discontinuation, assessed up to the end of the study (approximate 42 months)

    Incidence, nature, and severity of AEs graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v.5.0, and CRS and Immune effector cell-associated neurotoxicity syndrome (ICANS) graded according to the ASTCT Consensus Grading Criteria

  2. Dose Escalation part : Dose-limiting toxicities (DLTs) and PK profile of ALPS12[safety and tolerability]

    Time frame: From Cycle 1 Day 1 to the administration of ALPS12 on Cycle 2 Day 1 (Cycle 1 is 21 days)

    Nature and frequency of DLTs, AEs, PK and PD profiles

  3. Dose Escalation part : Immunogenicity of ALPS12

    Time frame: From screening until study completion or treatment discontinuation, assessed up to the end of the study (approximate 42 months)

    Incidence of ADAs to ALPS12 and potential correlation with PK parameters and safety

  4. Expansion part : Preliminary anti-tumor activity of ALPS12 when administered at selected dose(s) based on tumor assessment in patients with extensive stage SCLC

    Time frame: From screening until study completion or treatment discontinuation, assessed up to the end of the study (approximate 42 months)

    Objective response, defined as a confirmed complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1, as determined by the Investigators

Secondary outcomes

  1. Objective response rate(ORR)[preliminary efficacy]

    Time frame: From screening until study completion or treatment discontinuation, assessed up to the end of the study (approximate 42 months)

    ORR assessed per RECIST v.1.1 by the investigators.

  2. Disease control [preliminary efficacy]

    Time frame: From screening until study completion or treatment discontinuation, assessed up to the end of the study (approximate 42 months)

    defined as the proportion of patients who have CR, PR, or stable disease (SD) as best overall response per RECIST v.1.1 as determined by the investigator.

  3. Duration of response (DoR)[preliminary efficacy]

    Time frame: From screening until study completion or treatment discontinuation, assessed up to the end of the study (approximate 42 months)

    Duration of response (DoR), defined as the time from the first occurrence of CR or PR to progression disease (PD) or death from any cause (whichever occurs first), per the investigator according to RECIST v.1.1

  4. Progression-free survival (PFS)[preliminary efficacy]

    Time frame: From screening until study completion or treatment discontinuation, assessed up to the end of the study (approximate 42 months)

    Progression-free survival (PFS), defined as the time from administration of first study treatment to the first occurrence of disease progression or death from any cause, as determined by the investigator according to RECIST v.1.1

  5. Overall survival (OS)[preliminary efficacy]

    Time frame: From screening until study completion or treatment discontinuation, assessed up to the end of the study (approximate 42 months)

    Overall survival (OS), defined as the time from administration of first study treatment to death from any cause

  6. Immunogenicity of obinutuzumab

    Time frame: From screening until study completion or treatment discontinuation, assessed up to the end of the study (approximate 42 months)

    Incidence of ADAs to obinutuzumab and potential correlation with PK parameters and safety

  7. Maximum serum concentration (Cmax) and Area under the concentration time-curve (AUC) of ALPS12 with obinutuzumab[PK profile]

    Time frame: From screening until study completion or treatment discontinuation, assessed up to the end of the study (approximate 42 months)

    Serum ALPS12 concentration and its PK parameters including Cmax and AUC etc.

  8. Adverse events of obinutuzumab[safety and tolerability]

    Time frame: From screening until study completion or treatment discontinuation, assessed up to the end of the study (approximate 42 months)

    Incidence, nature, and severity of adverse events graded according to NCI Common Terminology CTCAE v5.0, with severity of CRS determined according to the American Society for Transplantation and Cell Therapy (ASTCT) Consensus Grading Criteria(In parts with obinutuzumab premedication)

Study contacts

Contact information is provided by the study sponsor or research team.

Clinical trials information

CONTACT

[email protected]

only use Email

Sponsors and collaborators

Lead sponsor

Chugai Pharmaceutical

Industry

Registry information

Official study title

AN OPEN-LABEL, MULTICENTER PHASE I STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND PRELIMINARY ANTI-TUMOR ACTIVITY OF ALPS12 IN PATIENTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER

Important dates

Study start
2025
Primary completion
2028
Study completion
2028
First posted
Aug 6, 2025
Registry last updated
Feb 6, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.